Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Natera sells molecular diagnostic tests that screen for cancer, genetic conditions in pregnancy, and organ transplant rejection.
Natera is a diagnostics company that sells blood tests which look for tiny traces of genetic material to answer big medical questions. Its tests serve three main groups: pregnant women checking on the health of a baby, cancer patients and their doctors, and organ transplant patients whose bodies might be rejecting a new organ.
The pregnancy business, built around a test called Panorama, screens for chromosomal conditions like Down syndrome early in pregnancy. Natera's edge is a clever counting method: it looks at millions of tiny DNA fragments in the mother's blood and uses statistics to tell which ones came from the baby. A second product, Empower, screens for inherited cancer risk. The cancer business is the growth engine now. Its Signatera test takes a sample of a patient's tumor, learns its genetic signature, then hunts for that signature in blood after surgery or treatment. If it shows up, cancer cells are lurking. Doctors use it to decide who needs more treatment and to catch relapse early, and drug companies use it to run better clinical trials. The transplant test, Prospera, checks whether a transplanted kidney or heart is being attacked by the immune system, which can be a quieter, safer alternative to invasive biopsies. The company's real moat is data. Every test it runs feeds a giant library of genetic patterns that makes the next test more accurate — a flywheel competitors must spend years and fortunes to match. The catch is that this is a costly, grinding business. Natera spends heavily on research and on fighting for insurance coverage, and it has a history of losses. Rivals include Guardant Health in cancer blood testing and Illumina-spawned Grail, while traditional labs compete on prenatal screening. Growth has been strong, with revenue climbing sharply in recent years as Signatera orders piled up, and the company has pushed toward profitability as test volume scaled.
The stock has been a wild ride, swinging on coverage decisions, clinical data, and short-seller attacks questioning its billing practices — a reminder that in diagnostics, the science is only half the battle; the other half is convincing insurers to pay.
Saved answer · last researched 15 Nov 2026